Sun Y, Zhu Z, Yang L. Analysis of key elements of pooled procurement programs in foreign countries and enlightenment to China. World Clin Drug. 2021;42(12):1062–5.

Google Scholar 

Ahmadi A, Heydari M, Pishvaee MS, et al. Strategic decisions to join group purchasing organizations. Comput Ind Eng. 2020;149: 106869.

Article  Google Scholar 

Bernard LW. The role of group purchasing organizations (GPOs) in the US medical industry supply chain. Estud de Econ. 2006;24(3):789–802.

Google Scholar 

Blair RD, Durrance CP. Group purchasing organizations, monopsony, and antitrust policy. Manag Decis Econ. 2014;35(7):433–43.

Article  Google Scholar 

IBIS World. Group Purchasing Organizations in the US—Market Size 2005–2029. 2023. https://www.ibisworld.com/industry-statistics/market-size/group-purchasing-organizations-united-states/. Accessed 20 May 2024.

Pierre D, Yassine L, Stephane S. Pooled procurement of drugs in low and middle income countries. Eur Econ Rev. 2021;132: 103655.

Article  Google Scholar 

Parmaksiz K, Pisani E, Bal R, et al. A systematic review of pooled procurement of medicines and vaccines: identifying elements of success. Glob Health. 2022;18(1):59.

Article  Google Scholar 

Vogler S, Habimana K, Haasis MA. Purchasing medicines for the public sector: evaluation of the performance of andomized procurement in Portugal. Int J Health Plann Manage. 2022;37(4):2007–31.

Article  PubMed  Google Scholar 

Vogler S, Bauer E, Habimana K. Centralised pharmaceutical procurement: learnings from six european countries. Appl Health Econ Health Policy. 2022;20(5):637–50.

Article  PubMed  Google Scholar 

Deng F, Lv JH, Wang HL, et al. Expanding public health in China: an empirical analysis of healthcare inputs and outputs. Public Health. 2017;142:73–84.

Article  PubMed  CAS  Google Scholar 

Li Z, Shen W, Zhang T. Research on the improvement mechanism of value-based healthcare objectives in pharmaceutical group procurement. Heliyon. 2024;10(7): e28170.

Article  PubMed  PubMed Central  Google Scholar 

General Office of the State Council of China. Notice on the issuance of the pilot program for the centralized purchase and use of drugs organized by the state. 2019. https://www.gov.cn/zhengce/content/2019-01/17/content_5358604.htm. Accessed 20 May 2024.

General Office of the State Council of China. Opinions on consistency evaluation of quality and efficacy of generic drugs. 2016. https://www.gov.cn/gongbao/content/2016/content_5054719.htm. Accessed 20 May 2024.

Zhang QY, Wang Y, Hu YX, et al. Implementation status and suggestions of centralized volume-based procurement policy for drugs and medical consumables in China. China Pharm. 2022;33(2):136–41.

Google Scholar 

Zhu Z, Wang Q, Sun Q, et al. Improving access to medicines and beyond: the national volume-based procurement policy in China. BMJ Glob Health. 2023;8(7): e011535.

Article  PubMed  PubMed Central  Google Scholar 

Cheng XW, Liu XH, Zhang SY, et al. Research on the impact of national drug centralized procurement policy on the innovation of pharmaceutical enterprises. Chin Pharm Aff. 2023;37(10):1101–9.

Google Scholar 

Chen M, Cong L, He J, et al. Prospects for development of group purchasing organizations (GPOs) in China within the context of national centralized drug procurement. Drug Discov Ther. 2020;14(3):145–8.

Article  PubMed  Google Scholar 

Wang YH, Xu W, Lu NN, et al. Analysis of the effect of “4+7” centralized procurement policy implementation based on the drug sales data of 9 pilot regions. Chin J Health Policy. 2021;14(2):36–43.

CAS  Google Scholar 

Tao J, Li S, Xu Q, et al. Patients’ attitudes towards switching to national volume-based procurement (NVBP) drugs-a qualitative investigation in Wuhan, China. BMC Health Serv Res. 2023;23(1):62.

Article  PubMed  PubMed Central  Google Scholar 

Wang H, Huo YT, Zhuang Q. Does China improve social welfare after implementing the national volume-based procurement? Front Pharmacol. 2023;14:1178026.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang X, He X, Zhang P, et al. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis. Int J Equity Health. 2023;22(1):200.

Article  PubMed  PubMed Central  Google Scholar 

Howard JN, Harris I, Frank G, et al. Influencers of generic drug utilization: a systematic review. Res Social Adm Pharm. 2018;14(7):619–27.

Article  PubMed  Google Scholar 

Toverud EL, Hartmann K, Håkonsen H. A systematic review of physicians’ and pharmacists’ perspectives on generic drug use: what are the global challenges? Appl Health Econ Health Policy. 2015;13(1):S35–45.

Article  PubMed  Google Scholar 

Colgan S, Faasse K, Martin LR, et al. Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. BMJ Open. 2015;5(12): e008915.

Article  PubMed  PubMed Central  Google Scholar 

O’Brien EC, McCoy LA, Thomas L, et al. Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the CRUSADE Registry. Am Heart J. 2015;170(1):55–61.

Article  PubMed  Google Scholar 

Serebruany VL, Hall TS, Atar D, et al. Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System (FAERS). Eur Heart J Cardiovasc Pharmacother. 2019;5(4):210–5.

Article  PubMed  Google Scholar 

Rahman MM, Alatawi Y, Cheng N, et al. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the US Food and Drug Administration Adverse Event Reporting System (FAERS). Epilepsy Res. 2017;135:71–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Marimuthu SP, Iyer G, Segal JB, et al. Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot study. J Comp Eff Res. 2017;6(5):437–47.

Article  PubMed  PubMed Central  Google Scholar 

Alatawi Y, Rahman MM, Cheng N, et al. Brand vs generic adverse event reporting patterns: an authorized generic-controlled evaluation of cardiovascular medications. J Clin Pharm Ther. 2018;43(3):327–35.

Article  PubMed  CAS  Google Scholar 

Bohn J, Kortepeter C, Muñoz M, et al. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs. Clin Pharmacol Ther. 2015;97(5):508–17.

Article  PubMed  CAS  Google Scholar 

Iyer G, Marimuthu SP, Segal JB, et al. An algorithm to identify generic drugs in the FDA Adverse Event Reporting System. Drug Saf. 2017;40(9):799–808.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rahman MM, Alatawi Y, Cheng N, et al. Methodological considerations for comparison of brand versus generic versus authorized generic adverse event reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS). Clin Drug Investig. 2017;37(12):1143–52.

Article  PubMed  PubMed Central  Google Scholar 

Kalaria S, Spence O, Hong K, et al. Evaluation of switch-to-brand rates as a potential signal for therapeutic equivalency of generic antidepressants: a real-world retrospective cohort study. Clin Pharmacol Ther. 2021;110(2):443–51.

Article  PubMed  CAS  Google Scholar 

Ferguson W, Clapshaw L. Study of mental health outcomes associated with different brands of venlafaxine at the Kumeu medical centre from January 2017 to October 2018. Ther Adv Psychopharmacol. 2020;10:2045125320927309.

Article  PubMed  PubMed Central  Google Scholar 

Pennap DD, Swain RS, Welch EC, et al. Risk of hospitalized depression and intentional self-harm with brand and authorized generic sertraline. J Affect Disord. 2022;296:635–41.

Article  PubMed  CAS  Google Scholar 

Kharasch ED, Neiner A, Kraus K, et al. Bioequivalence and therapeutic equivalence of generic and brand bupropion in adults with major depression: a randomized clinical trial. Clin Pharmacol Ther. 2019;105(5):1164–74.

Article  PubMed  CAS  Google Scholar 

Holtkamp M, Theodore WH. Generic antiepileptic drugs-Safe or harmful in patients with epilepsy? Epilepsia. 2018;59(7):1273–81.

Article  PubMed